NCT06911073 A Study to Evaluate a Postbiotic in Supporting Weight Loss and Metabolic Health
| NCT ID | NCT06911073 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ResBiotic Nutrition, Inc. |
| Condition | Obesity and Overweight |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-05-02 |
| Primary Completion | 2025-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-05-02 with a primary completion date of 2025-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the impact of a specific oral postbiotic supplement on metabolic health in overweight adults.
Eligibility Criteria
Inclusion Criteria: 1. Provide voluntary signed and dated informed consent. 2. Be in good health as determined by medical history. 3. Age between 18 and 65 yr (inclusive). 4. Body Mass Index of 25.0 - 40.0 (inclusive). 5. Subject agrees to maintain existing dietary and physical activity patterns throughout the study period. 6. Agree to refrain from other probiotic and postbiotic supplement products throughout the duration of the trial. 7. Subject is willing and able to comply with the study protocol. 8. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures. Exclusion Criteria: 1. History of unstable or new-onset cardiovascular/cardiorespiratory, liver, or renal conditions. 2. Alcohol abuse (more than 2 standard alcoholic drinks per day or more than 10 drinks per week) or drug abuse or dependence within the past 6 months. 3. Previous bariatric surgery. 4. Current smokers or smoking within the past month. 5. History of hyperparathyroidism or an untreated thyroid condition. 6. History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin). 7. Other known gastrointestinal or metabolic conditions that might impact nutrient absorption or metabolism, e.g., short bowel syndrome, irritable bowel syndrome (IBS), diarrheal illnesses, history of colon resection, gastroparesis, Inborn-Errors-of-Metabolism (such as PKU). 8. Chronic inflammatory condition (e.g., rheumatoid arthritis, Crohn's, ulcerative colitis, Lupus, HIV/AIDS, etc.). 9. Previous medical diagnosis of gout or fibromyalgia. 10. Pregnant women, women trying to become pregnant, women less than 120 days postpartum or nursing women. Any woman that is sexually active will have to take report their pregnancy status prior to enrolling and during the trial if they become pregnant. 11. Known sensitivity to any ingredient in the test formulations as listed in the product label. 12. Currently participating in another research study with an investigational product or have been in another research study in the past 30 days.
Contact & Investigator
Ahmed Abdelgawad, MD
PRINCIPAL INVESTIGATOR
Able Biolabs, LLC
Frequently Asked Questions
Who can join the NCT06911073 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Obesity and Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06911073 currently recruiting?
Yes, NCT06911073 is actively recruiting participants. Contact the research team at clinical@ablebiolabs.com for enrollment information.
Where is the NCT06911073 trial being conducted?
This trial is being conducted at Birmingham, United States.
Who is sponsoring the NCT06911073 clinical trial?
NCT06911073 is sponsored by ResBiotic Nutrition, Inc.. The principal investigator is Ahmed Abdelgawad, MD at Able Biolabs, LLC. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.